According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
US President Joe Biden singled out the pharmaceutical industry in his recently issued Executive Order on Promoting Competition in the American Economy.
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.
The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
This month’s roundup of new equipment, materials, tech partnerships and other news includes items from Ajinomoto, Evonik, Quanticate, Pharmasol, and more.
An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.
Medable will collaborate with Aural Analytics in an initiative funded by the NIH’s seven-year Beau Biden Cancer Moonshot research and development program.
In recent years, it has become clear that RNA molecules are an emerging as a class of therapeutics of relevance to multiple diseases, most recently including COVID-19 vaccines.
Decentralized trials and remote monitoring, long discussed, but never really taking off until COVID-19 disrupted studies last year, will be under the spotlight at the DIA 2021 Annual Meeting at the end of this month.
Whether working in the pharmaceutical industry or in academia or government, the skills required to achieve, maintain and grow a career are vastly different today than they were 30 years ago. A session at DIA 2021 will put the spotlight on the skills...
In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.
COVID-19 vaccination via Vaxxas’ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.
The University of Kansas Cancer Center has joined with trial tech provider Complion to develop a shared investigator platform for use in a range of studies.
This month’s roundup of hires, acquisitions, anniversaries, and other announcements includes news from Premier Research, Cytel, ACG, and other companies.
The online pharma event will address the COVID-19 pandemic’s impact on the industry (and vice versa) and innovation in the face of formidable challenges.
Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes.
This month’s roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.
Published by Tabula Rasa Healthcare, the report looks at the MedWise Risk Score, technology designed to determine ADE risk rising from medication regimens.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The US Food and Drug Administration (FDA) has issued guidance for companies developing vaccines, diagnostics and therapeutics against new variants of SARS-CoV-2.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.